Pregabalin Open-Label Extension Trial in Patients With Partial Seizures

NCT00143143 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2006-07-24

No results posted yet for this study

Summary

The primary purpose of the protocol is to evaluate the long-term safety of pregabalin in patients with partial seizures.

Conditions

  • Epilepsies, Partial
  • Epilepsy, Complex Partial

Interventions

DRUG

Pregabalin

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-09-30
Completion
2006-02-28

Countries

  • Austria
  • Canada
  • France
  • Germany
  • Italy
  • Lithuania
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00143143 on ClinicalTrials.gov